WHERE THE EVIDENCE STANDS
Semaglutide sits on the largest evidence base of any compound on this site, including cardiovascular outcome trials. The 2026 record is about use outside the trials: persistence rising to 60.9 % at one year, falling physical activity among users, and musculoskeletal signals in claims data. A Yale study in August 2026 proposed a revised account of how the class acts on hunger circuits.
On 30 April 2026 the FDA proposed excluding semaglutide from the 503B bulks list, which would close the outsourcing-facility compounding route opened during the shortage years. Reports cite more than 455 adverse-event reports tied to compounded semaglutide.
ENTRIES ABOUT Semaglutide · 4
PAPER
Researchers at Yale report that GLP-1 therapies recruit agouti-related peptide neurons, long treated as drivers of hunger, to help maintain fat loss.
PAPER
Reports in 2026 describe falling physical activity among people on GLP-1 drugs, claims-data signals on bone and joint conditions with long-term use, and one-year persistence nearly doubling since 2021.
REGULATION
A 30 April 2026 proposal would exclude the three GLP-1 drugs from the 503B bulks list, closing the outsourcing-facility route that opened during the shortage years.
TRIAL
April 2026 brought approval of orforglipron, the first oral small-molecule GLP-1 receptor agonist. Oral options so far produce less weight reduction than leading injectables but are easier to make and take.
SOURCES
- Drug Discovery News. GLP-1 agonist clinical pipeline 2026. 26 Jun 2026. News feature. https://www.drugdiscoverynews.com/glp-1-agonist-clinical-pipeline-2026-semaglutide-tirzepatide-and-what-s-in-phase-2-17286
- Pharmacy Times. FDA moves to permanently close the door on compounded GLP-1s. 1 May 2026. News report. https://www.pharmacytimes.com/view/fda-moves-to-permanently-close-the-door-on-compounded-glp-1s
REVIEWED 5 Oct 2026 · NEXT REVIEW JAN 2027 · CORRECTIONS ARE LOGGED HERE